Summary
The CLIMATE study (ANZUP 1906) assessed whether plasma microRNA miR-371a-3p, measured after orchiectomy, can predict relapse in patients with stage I germ cell testicular cancer and help decide who truly needs adjuvant chemotherapy. The preliminary results, presented at the 2026 ASCO Genitourinary Cancers Symposium, place it as the most promising lead to date, but it is not yet ready for routine clinical use.
Clinical problem
In stage I testicular cancer, most patients are cured by orchiectomy alone and can follow active surveillance. A minority relapse, however; adjuvant BEP chemotherapy reduces that risk but exposes many patients who do not need it to unnecessary toxicity.
The challenge is to identify more precisely those with microscopic residual disease and a truly high risk of relapse. Current factors, such as tumor size, lymphovascular invasion, or models like Boormans, are imperfect.
What miR-371 is
miR-371a-3p is a microRNA expressed by germ cell tumors and detectable in blood. Its half-life is very short, 3 to 7 hours, so a positive result shortly after surgery suggests viable residual tumor rather than simply slow clearance of the marker. It does not detect teratoma, which does not express this microRNA.
Study design
CLIMATE prospectively enrolled 200 patients from Australia and New Zealand with stage I germ cell testicular cancer, both seminoma and non-seminoma, with a median age of 33 years. All were followed with active surveillance after orchiectomy, without initial adjuvant chemotherapy.
Blood samples were collected at baseline, within 6 weeks of surgery, and every 3 months for 2 years. The interim analysis focused on the baseline sample, available for 196 patients and collected a median of 29 days after orchiectomy.
Main results
| Measure | Plasma miR-371 | Serum miR-371 |
|---|---|---|
| Patients with a positive result | 42 | 34 |
| Positive predictive value | 62% | 56% |
| Negative predictive value | 91% | 87% |
| Area under the curve (AUC) | 0.77 | 0.69 |
Plasma was superior to serum, so subsequent analyses were based on plasma.
A positive plasma miR-371 was associated with an approximately 10-fold higher risk of relapse (HR 10.3; P < .001). At 24 months, relapse-free survival was 32% in those with a positive result versus 89% in those with a negative result.
In a sensitivity analysis including patients without relapse who had at least 24 months of follow-up, the positive predictive value was 93%, the negative predictive value 75%, and the AUC 0.80.
Comparison with current factors
In pure seminoma, miR-371 had an AUC of 0.86, higher than the Boormans model (0.63) and tumor size greater than 40 mm (0.60). In non-seminomatous tumors, it had an AUC of 0.72, better than lymphovascular invasion (0.58) and embryonal carcinoma (0.53).
In addition, in patients already considered intermediate or high risk, a positive miR-371 further improved the ability to identify relapse: HR 21.9 in the Boormans intermediate/high-risk group and HR 4.2 in patients with lymphovascular invasion.
Limitations
- It is an interim analysis with a median follow-up of 18.9 months; some recurrences may appear later.
- Of the 40 patients who relapsed, 14 had a negative baseline miR-371, showing that the test does not detect every relapse.
- Of the 156 patients who did not relapse, 16 were positive at baseline; 5 of them had less than 12 months of follow-up.
- The marker does not identify teratoma, an important biological limitation in some non-seminomatous tumors.
- Measurement methods vary between institutions, and it is still unknown how to act on a positive result: when to treat, with what, and whether early detection actually improves outcomes.
Practical implications
According to the investigator who presented the work, post-orchiectomy plasma miR-371 has the potential to optimize selection of patients who would benefit from adjuvant chemotherapy and spare the rest unnecessary treatment.
However, the discussant, Samuel A. Funt, noted that there are currently too many barriers, questions, and potential pitfalls for use in routine clinical decisions, and called it the most promising lead to date. The next step is interventional trials to determine whether a positive result, or its rise during surveillance, should change management and whether this improves outcomes without increasing unnecessary treatment. The final analysis will include complete follow-up of all 200 patients and serial samples, and external validation is ongoing.
Source
Helwick C. Plasma miR-371a-3p predicts recurrence in stage I testicular cancer: interim results from the CLIMATE study. The ASCO Post, May 10, 2026. Link